UNSPSC 51162407: Caramiphen/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE512. This VA Drug Class (RE512) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE.

UNSPSC 51162407 Caramiphen/phenylpropanolamine is a Commodity code that covers pharmaceutical products, including naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals with over-the-counter alternatives that state and local health agencies, county health departments, and cooperative purchasing alliances procure to support community health and emergency response initiatives. State and local governments buying under this code range from individual county health departments to multistate cooperative purchasing consortiums; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, are recent active buyers. The work involves supplying pharmaceutical products in bulk quantities with specific National Drug Codes (NDC), supporting quarterly or regular distribution to health facilities and emergency response programs, and meeting cGMP certification, Drug Supply Chain Security Act compliance, and FDA requirements including minimum shelf-life specifications.

Recent activity spans Florida and the upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. MMCAP issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026; vendors must work through authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) and maintain commercial general liability insurance of $5,000,000 per occurrence, with awarded contracts effective July 1, 2026.